ArticleInternational journal for parasitology. Drugs and drug resistance2025
Pharmacokinetics and metabolism of artemisinin (ART) in Plasmodium yoelii: ART-heme adduct as a potential biomarker for its resistance.
Article in International journal for parasitology. Drugs and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heme as activator and target for artemisinin: Towards multiple pharmacological bioactivity.Biochemistry and biophysics reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmodium falciparum in Southeast Asia and Africa is developing resistance to the antimalarial drug artemisinin (ART). In this study, the metabolite of ART in P. yoelii parasites was evaluated as a potential biomarker for its antimalarial activity as well as its resistance.
methodsThe induced strain of P. yoelii (iPy) was first established after long-time pressure of ART in P. yoelii (Py)-infected mice. The metabolic and pharmacokinetic profiles of ART were then studied in both P. yoelii parasites and infected mice. The pharmacokinetic-pharmacodynamic behaviors of ART in two strains of P. yoelii (Py and iPy) were compared. The pharmacokinetic parameters (e.g., AUC and C
resultsLower antimalarial activity was found for ART against iPy than Py, in terms of the 90 % growth inhibitory dose (ED
conclusionsPlasma ART concentration merely reflected drug exposure in the host. ART-heme adduct was the major metabolite for ART in P. yoelii parasites, and it could be a potential biomarker for the antimalarial activity of ART as well as its resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.